Keyword: Zostavax

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

Here is some other vaccine news of note for the week.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.

GlaxoSmithKline picked up two important Shingrix nods from regulators in Europe and Japan.

Glaxo's important new vaccine Shingrix will be available at more than 9,800 CVS pharmacies, giving the shingles shot a broad launch platform.

It's believed that SK Chemicals is stealing shingles vaccine share from Zostavax by undercutting the pharma giant's price.

Despite new challenges in shingles, Merck's vaccine business kept churning in 2017, generating sales of $6.5 billion—an increase of 4.8%.

Merck is projecting a flat tax rate this year as many of its peers expect to see a benefit.

After picking up key regulatory nods in the U.S., GlaxoSmithKline’s Shingrix is well on its way to expanding its reach into Europe.

Merck's star HPV vaccine missed sales expectations in the third quarter as the company had to borrow from the CDC stockpile to fulfill orders.